Journal of medical Internet research
June 17, 2026
Acacia C Parks, Amanda L Woodward, Robert D Henry et al.
A large analysis of 3,870 patients with moderate-to-severe depression, anxiety, or PTSD who used a telehealth program for at-home subcutaneous ketamine found significant symptom reductions after about six weeks. Depression scores on the PHQ-9 fell from 14.6 to 6.3, anxiety scores on the GAD-7 from 13.1 to 6.1, and PTSD scores on the PCL-5 from 46.7 to 27.5, all with large effect sizes. Over 80% of patients achieved a clinically meaningful improvement. Adverse events were low (2.8%-3.2%), and no serious complications occurred. The results suggest that supervised at-home subcutaneous ketamine is a safe and effective option that could expand access to rapid-acting treatment.
Research Square
February 11, 2026
Jack Swain, Davis Carter, Leonardo Vando
Among 374 adults with moderate-to-severe PTSD who completed six sessions of at-home, telehealth-supported ketamine-assisted therapy, PTSD symptoms improved substantially. Mean PCL-5 scores dropped from 51.1 at baseline to 28.3 after session 6, a 44.6% reduction. The clinical response rate was 79.7%, and 60.7% achieved remission. Suicidal ideation resolved completely in 75.9% of those who reported it at baseline. Depression and anxiety scores also declined by about half. Side effects occurred in 4.3% of participants. Controlled trials are needed to confirm causality.
Acacia C Parks, Amanda L Woodward, Robert D Henry et al.
A telehealth-supervised at-home subcutaneous ketamine protocol for moderate-to-severe depression, anxiety, and PTSD was safe, feasible, and highly effective. Among 3,870 patients, symptom scores dropped from moderate-to-severe to mild or subthreshold ranges after about six weekly sessions: depression scores fell from 14.64 to 6.30, anxiety from 13.06 to 6.09, and PTSD from 46.7 to 27.5, with large effect sizes. Clinically meaningful improvement occurred in 80% to 84.6% of patients, depending on condition. Adverse events were low (2.8%–3.2%), and no serious complications were reported. The model offers a lower-cost, high-bioavailability alternative to in-clinic ketamine infusions.
Research Square
Jack Swain, Davis Carter, Leonardo Vando et al.
Among 13,963 adults with moderate-to-severe sleep disturbances who received at-home ketamine-assisted therapy for depression, 67.4% showed at least a 1-point improvement on a single sleep-related item from a depression screening tool after two sessions. By session six, 76.8% of completers met that threshold, and the average score dropped 48.8% from baseline. However, the study could not separate sleep changes from mood improvement because all participants were treated for depression and no control group was included. Side effects were reported by 3.7% to 5.0% of participants across sessions.